Huang Xin, Guo Haoyu, Wang Lutong, Zhang Zhicai, Zhang Weiyue
Department of Orthopaedics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
Department of Orthopaedics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
Drug Discov Today. 2023 Apr;28(4):103514. doi: 10.1016/j.drudis.2023.103514. Epub 2023 Feb 2.
Small interfering RNA (siRNA) therapeutics for cancer are a focus of increasing research interest. However, the major obstacle to their clinical application is the targeted delivery of siRNA to cancer cells at desirable levels. Cell membrane-coated nanocarriers have the advantage of combining the properties of both cell membranes and nanoparticles (NPs). In this review, we highlight the most common RNAi therapeutics and the extracellular and intracellular barriers to siRNA delivery. Moreover, we discuss clinical applications of different cell membrane-coated nanocarriers for targeted siRNA delivery, including cancer cell membranes (CCMs), platelet membranes, erythrocyte membranes, stem cell membranes, exosome membranes, and hybrid membranes. Taken together, biomimetic cell membrane-coated nanotechnology is a promising strategy for targeted siRNA delivery for cancer treatment.
用于癌症治疗的小分子干扰RNA（siRNA）疗法是越来越受研究关注的焦点。然而，其临床应用的主要障碍是将siRNA以理想水平靶向递送至癌细胞。细胞膜包覆的纳米载体具有结合细胞膜和纳米颗粒（NP）两者特性的优势。在本综述中，我们重点介绍了最常见的RNAi疗法以及siRNA递送的细胞外和细胞内障碍。此外，我们还讨论了不同细胞膜包覆的纳米载体用于靶向siRNA递送的临床应用，包括癌细胞膜（CCM）、血小板膜、红细胞膜、干细胞膜、外泌体膜和混合膜。综上所述，仿生细胞膜包覆纳米技术是一种用于癌症治疗的靶向siRNA递送的有前景的策略。
